Angioimmunoblastic T cell lymphoma (AITL) is one of the most common T-cell lymphomas, second only to peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). Initially AITL was considered a non-malignant lymphadenopathy with immune hyperactivation, nowadays being classified as a PTCL.

The recently published manuscript entitled “Epigenetically Altered T Cells Contribute to Lupus Flares” summarizes recent advances in our understanding of how the environment alters the immune system to cause flares of systemic lupus erythematosus (SLE) in genetically predisposed people, and why it affects women approximately 9 times more often than men

CAR-T cell immunotherapy is a great advance in hematological cancers treatment. New CARs and therapy schemes are being developed and a mathematical model could contribute to a rational design of treatment. Here we comment and show new results with previously published models of CAR-T cell therapy, emphasizing the contribution of initial tumor load, the proliferation of CAR-T cell and inhibition of CAR-T cell activity by the tumor resulting in different scenarios as tumor escape, equilibrium (stable disease) and tumor elimination.

Since the discovery of escaping mechanism of tumor from negative immune regulation, the paradigm of drug discovery for anti-cancer agents has been dramatically shifted to cancer immunotherapy (e.g., dendritic cell therapy, CAR-T cell therapy, or antibody therapy) by stimulating patient’s immune system to treat cancer. 

In 1989, researchers proposed an intricate strategy in the field of adoptive cell therapy (ACT). Using the T-cell receptor (TCR) as a template, they replaced the coding sequence for the Vα and Vβ chains with the antigen- recognition domains from an antibody (VH and VL chains).